3 assets in Chronic Graft Versus Host Disease

Therapeutic assets addressing Chronic Graft Versus Host Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ibrutinib Chronic Graft Versus Host Disease	Janssen Research & Development, LLC	P3	B (60)
Vimseltinib Chronic Graft Versus Host Disease	Deciphera Pharmaceuticals, LLC	P2	CCC (53)
trx103 Chronic Graft Versus Host Disease	Tr1X, Inc.	P1	NR ()